Senescence‑associated IL‑33 secretion undermines sorafenib efficacy in hepatocellular carcinoma via immune evasion
Oncology Reports · 2025
DOI: 10.3892/or.2025.8987 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Reports, 2025. Verfasst von Yu-Xin Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan. Hauptthemen laut MEDLINE: Sorafenib, Carcinoma, Hepatocellular, Liver Neoplasms, Interleukin-33. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
- Division of General Surgery, Department of Surgery, Ditmanson Medical Foundation Chia‑Yi Christian Hospital, Chiayi 60002,Taiwan.
- Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
- Department of Pathology, Ditmanson Medical Foundation Chia‑Yi Christian Hospital, Chiayi 60002, Taiwan.
Zitieren
APA
Lin, Y. X., Liu, H., Liao, W. C., Wang, Y. C., Zhang, B. C., Wan, S. W., Chen, C. C., & Chang, C. P. (2025). Senescence‑associated IL‑33 secretion undermines sorafenib efficacy in hepatocellular carcinoma via immune evasion. Oncology Reports. https://doi.org/10.3892/or.2025.8987
Vancouver
Lin YX, Liu H, Liao WC, Wang YC, Zhang BC, Wan SW, et al. Senescence‑associated IL‑33 secretion undermines sorafenib efficacy in hepatocellular carcinoma via immune evasion. Oncology Reports. 2025. doi:10.3892/or.2025.8987
BibTeX
@article{Lin2025,
author = {Lin, Yu-Xin and Liu, Hsien and Liao, Wei-Chiao and Wang, Yi-Ching and Zhang, Bo-Cheng and Wan, Shu-Wen and Chen, Chien-Chin and Chang, Chih-Peng},
title = {Senescence‑associated IL‑33 secretion undermines sorafenib efficacy in hepatocellular carcinoma via immune evasion},
journal = {Oncology Reports},
year = {2025},
doi = {10.3892/or.2025.8987}
}
EUVIMED